FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2547255159> ?p ?o ?g. }

• W2547255159 endingPage "52" @default.
• W2547255159 startingPage "43" @default.
• W2547255159 abstract "To assess the efficacy of 2 forms of oral long-chain omega-3 (ω-3) essential fatty acid (EFA) supplements, phospholipid (krill oil) and triacylglyceride (fish oil), for treating dry eye disease (DED).Randomized, double-masked, placebo-controlled clinical trial.This study was conducted at a single site and involved 60 participants with mild to moderate DED who were randomized (1:1:1) to 1 of 3 groups: placebo (olive oil), krill oil, or fish oil supplements.Participants received 1 of the 3 interventions: placebo (olive oil 1500 mg/day), krill oil (945 mg/day eicosapentaenoic acid [EPA], + 510 mg/day docosahexaenoic acid [DHA]), or fish oil (1000 mg/day EPA + 500 mg/day DHA) for 90 days, with monthly study visits.Primary outcome measures were mean change in (1) tear osmolarity and (2) DED symptoms (Ocular Surface Disease Index [OSDI] score) between days 1 and 90. Secondary outcomes included mean change in key clinical signs (tear stability, tear production, ocular surface staining, bulbar and limbal redness, tear volume, anterior blepharitis, meibomian gland capping) and tear inflammatory cytokine levels.In total, 54 participants completed the study. At day 90, tear osmolarity was reduced from baseline with both krill oil (mean ± standard error of the mean: -18.6±4.5 mOsmol/l; n = 18; P < 0.001) and fish oil (-19.8±3.9 mOsmol/l; n = 19; P < 0.001) supplements, compared with placebo (-1.5±4.4 mOsmol/l; n = 17). OSDI score was significantly reduced at day 90 relative to baseline in the krill oil group only, compared with placebo (-18.6±2.4 vs. -10.5±3.3; P = 0.02). At day 90, there were also relative improvements in tear breakup time and ocular bulbar redness, compared with placebo, for both forms of ω-3 EFAs. Basal tear levels of the proinflammatory cytokine interleukin 17A were significantly reduced in the krill oil group, compared with placebo, at day 90 (-27.1±10.9 vs. 46.5±30.4 pg/ml; P = 0.02).A moderate daily dose of both forms of long-chain ω-3 EFAs, for 3 months, resulted in reduced tear osmolarity and increased tear stability in people with DED. Omega-3 EFAs in a predominantly phospholipid form (krill oil) may confer additional therapeutic benefit, with improvements in DED symptoms and lower basal tear levels of interleukin 17A, relative to placebo." @default.
• W2547255159 created "2016-11-11" @default.
• W2547255159 creator A5007706989 @default.
• W2547255159 creator A5007840204 @default.
• W2547255159 creator A5021118701 @default.
• W2547255159 creator A5027270996 @default.
• W2547255159 creator A5035122969 @default.
• W2547255159 creator A5071899611 @default.
• W2547255159 date "2017-01-01" @default.
• W2547255159 modified "2023-10-13" @default.
• W2547255159 title "A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease" @default.
• W2547255159 cites W1934742528 @default.
• W2547255159 cites W1968528693 @default.
• W2547255159 cites W1975973163 @default.
• W2547255159 cites W1982767852 @default.
• W2547255159 cites W1984864129 @default.
• W2547255159 cites W1987200266 @default.
• W2547255159 cites W1988318286 @default.
• W2547255159 cites W1989661936 @default.
• W2547255159 cites W1997315139 @default.
• W2547255159 cites W2001682689 @default.
• W2547255159 cites W2002180108 @default.
• W2547255159 cites W2005077929 @default.
• W2547255159 cites W2011777137 @default.
• W2547255159 cites W2012144205 @default.
• W2547255159 cites W2013281526 @default.
• W2547255159 cites W2019497137 @default.
• W2547255159 cites W2024054650 @default.
• W2547255159 cites W2027616237 @default.
• W2547255159 cites W2027998563 @default.
• W2547255159 cites W2031979684 @default.
• W2547255159 cites W2044127304 @default.
• W2547255159 cites W2046439573 @default.
• W2547255159 cites W2055370551 @default.
• W2547255159 cites W2056565496 @default.
• W2547255159 cites W2066618391 @default.
• W2547255159 cites W2067545345 @default.
• W2547255159 cites W2068584868 @default.
• W2547255159 cites W2070610048 @default.
• W2547255159 cites W2075995435 @default.
• W2547255159 cites W2087432600 @default.
• W2547255159 cites W2088119156 @default.
• W2547255159 cites W2091630088 @default.
• W2547255159 cites W2092244914 @default.
• W2547255159 cites W2097958521 @default.
• W2547255159 cites W2112105480 @default.
• W2547255159 cites W2126039574 @default.
• W2547255159 cites W2127030148 @default.
• W2547255159 cites W2140531245 @default.
• W2547255159 cites W2141860584 @default.
• W2547255159 cites W2143812296 @default.
• W2547255159 cites W2154266087 @default.
• W2547255159 cites W2158113786 @default.
• W2547255159 cites W2167601697 @default.
• W2547255159 cites W2325074872 @default.
• W2547255159 cites W2417115835 @default.
• W2547255159 cites W2493099616 @default.
• W2547255159 cites W2521601013 @default.
• W2547255159 cites W2596391620 @default.
• W2547255159 cites W2597267452 @default.
• W2547255159 cites W2768450017 @default.
• W2547255159 cites W4236805817 @default.
• W2547255159 doi "https://doi.org/10.1016/j.ophtha.2016.09.023" @default.
• W2547255159 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27817918" @default.
• W2547255159 hasPublicationYear "2017" @default.
• W2547255159 type Work @default.
• W2547255159 sameAs 2547255159 @default.
• W2547255159 citedByCount "110" @default.
• W2547255159 countsByYear W25472551592017 @default.
• W2547255159 countsByYear W25472551592018 @default.
• W2547255159 countsByYear W25472551592019 @default.
• W2547255159 countsByYear W25472551592020 @default.
• W2547255159 countsByYear W25472551592021 @default.
• W2547255159 countsByYear W25472551592022 @default.
• W2547255159 countsByYear W25472551592023 @default.
• W2547255159 crossrefType "journal-article" @default.
• W2547255159 hasAuthorship W2547255159A5007706989 @default.
• W2547255159 hasAuthorship W2547255159A5007840204 @default.
• W2547255159 hasAuthorship W2547255159A5021118701 @default.
• W2547255159 hasAuthorship W2547255159A5027270996 @default.
• W2547255159 hasAuthorship W2547255159A5035122969 @default.
• W2547255159 hasAuthorship W2547255159A5071899611 @default.
• W2547255159 hasBestOaLocation W25472551591 @default.
• W2547255159 hasConcept C118487528 @default.
• W2547255159 hasConcept C126322002 @default.
• W2547255159 hasConcept C142724271 @default.
• W2547255159 hasConcept C19038510 @default.
• W2547255159 hasConcept C204787440 @default.
• W2547255159 hasConcept C27081682 @default.
• W2547255159 hasConcept C2776091944 @default.
• W2547255159 hasConcept C2777165675 @default.
• W2547255159 hasConcept C2777171753 @default.
• W2547255159 hasConcept C2779946292 @default.
• W2547255159 hasConcept C2781302119 @default.
• W2547255159 hasConcept C2909208804 @default.
• W2547255159 hasConcept C505870484 @default.
• W2547255159 hasConcept C543025807 @default.
• W2547255159 hasConcept C55493867 @default.

• next